Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 274-281

  Mikulski, Stanislaw M ^a   Costanzi, John J ^a   Vogelzang, Nicholas J ^a   McCachren, Spence ^a   Taub, Robert N ^a   Chun, Hoo ^a   Mittelman, Abraham ^a   Panella, Timothy ^a   Puccio, Carmelo ^a   Fine, Robert ^a   Shogen, Kuslima ^a  

^a Alfacell Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; IDOXURIDINE; IFOSFAMIDE; INTERLEUKIN 3; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; RANPIRNASE; RIBONUCLEASE; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; NEPHROTOXICITY; ONCOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MESOTHELIOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RIBONUCLEASES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 0036137925     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.274     Document Type: Article

References (24)

1. Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1968-1985
2. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience
3. A review of chemotherapy trials for malignant mesothelioma
4. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma
5. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 331 patients
6. Malignant mesothelioma of the pleura
7. Malignant pleural mesothelioma: A survival study
8. The importance of surgical staging in the treatment of malignant pleural mesothelioma
9. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos: Homology to pancreatic ribonucleases
10. A cytotoxic ribonuclease: Study of the mechanism of Onconase cytotoxicity
11. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease Onconase: Evidence for cytotoxic mechanisms different from inhibition of protein synthesis
12. K1P and decreased pRb phosphorylation
13. Cytostatic and cytotoxic effects of Pannon (P-30 protein), a novel anticancer agent
14. Transformed cells have lost control of ribosome number through their growth cycle
15. Control of cellular proliferation in HeLa-S3 suspension cultures: Characterization of cultures utilizing acridine orange staining procedures
16. The use of Onconase for patients with advanced malignant mesothelioma
17. Phase I human clinical trial of Onconase (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors
18. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B (CALGB)
19. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
20. Phase III randomized trial of Onconase (ONC) vs. doxorubicin (DOX) in patients (pts) with unresectable malignant mesothelioma (UMM): Analysis of survival
21. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B
22. Onconase and doxorubicin synergy in prolonging survival of MDA-MB-231 human breast cancer-bearing nude mice
23. In vitro synergism between a novel amphibian oocytic ribonuclease (Onconase) and tamoxifen, lovastatin, and cisplatin in human OVCAR-3 ovarian carcinoma cell line